SPPH Spencer Pharmaceutical Inc (CE)

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces that it concluded Pharmacokinetic experiments with Ibuprofen (anti-inflammatory) formulated process following Spencer Pharmaceutical recently patented formulations for anti-inflammatory drugs.

Management is pleased to report that preliminary results of a Pharmacokinetic study conducted in dogs (beagle) by an independent Contract Research Organization, following strictly regulated protocols, using coded products with Ibuprofen formulation according to Spencer Pharmaceutical Inc. patented formulations, showed the rapid release of the active ingredient. In addition, the effective concentrations of the active ingredient lasted for a longer period (up to 12 hours) after administration of a single dose. These concentrations are similar to those obtained after repeated administration with conventional forms of commercial product that requires a tablet every 4 hours.

"Clearly to the lay investor the above announcement may appear a bit dry. However, in reality these animal test results mirror our earlier in-vitro (lab bench tests) findings and move our product a step forward to its pharmaceutical development and to our eventual goal of commercializing our new patent in the $multi-billion annual anti-inflammatory medical market globally," explained Dr. Max Arella, CEO of Spencer Pharmaceutical Inc. Furthermore "our next step with these excipients for anti-inflammatory formulation will be to prepare the proper documentation for meeting with Regulatory authorities and for subsequent Clinical studies in the near term," added Dr. Arella.

Management of Spencer is keeping Al-Dorra and its subsidiary Hail First Pharma updated on these exciting new developments as they are diligently working on the buyout transactions and continuing updates are scheduled to be released to shareholders.

Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information

About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release. Although there is an offer currently coming from a third party, the Company can provide no assurances that the offer will be made, the timelines achieved, or the minimum offer will be realized.

Contact: Ian Morrice Executive Vice President and Director Spencer Pharmaceutical Inc. +1 (617) 973-5017